<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00807989</url>
  </required_header>
  <id_info>
    <org_study_id>109887</org_study_id>
    <nct_id>NCT00807989</nct_id>
  </id_info>
  <brief_title>The Efficacy and Safety of Low Dose Combination of LTG and VPA Compared to CBZ Monotherapy</brief_title>
  <official_title>An Open Label, Randomized, Multicenter Clinical Trial to Compare the Efficacy and Safety of Lamotrigine / Valproate Coadministration and Carbamazepine as Initial Pharmacotherapy in Epilepsies (Phase Ⅳ)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Yonsei University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Yonsei University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      To evaluate the efficacy of usual monotherapy and low dose combination of Lamotrigine and
      Valproate. Low dose combination may be more effective and tolerable because they are low dose
      and VPA reduce Lamotrigine metabolism.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      An Open label, Randomized, Multicenter Clinical Trial to Compare the Efficacy and Safety of
      Lamotrigine / Valproate Coadministration and Carbamazepine as Initial Pharmacotherapy in
      Epilepsies
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>March 2008</start_date>
  <completion_date type="Actual">May 2012</completion_date>
  <primary_completion_date type="Actual">May 2012</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Retention Rate After 52 Weeks Maintenance Period</measure>
    <time_frame>52 weeks</time_frame>
    <description>* Retention rate means completion rate (CR), the proportion of patients who have completed the 60-week study as planned.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Seizure Free Rate for 24 Weeks at Initial Target Dose</measure>
    <time_frame>24 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Seizure Free Rate for 52 Weeks at Initial Target Dose</measure>
    <time_frame>52 weeks</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">207</enrollment>
  <condition>Epilepsy</condition>
  <arm_group>
    <arm_group_label>Carbamazepine</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Carbamazepine</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Lamotrigine/Valproate</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Lamotrigine and Valproate combination therapy</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Carbamazepine</intervention_name>
    <arm_group_label>Carbamazepine</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Lamotrigine/Valproate</intervention_name>
    <arm_group_label>Lamotrigine/Valproate</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Age ≥16yr old

          -  Who are diagnosed as epilepsy definitely

          -  Who have minimum 2 unprovoked seizures and minimum 1 seizure in previous 3 months

          -  Who need AED therapy and no AED medication for previous 1 year (exclude emergency
             medication for less than 2weeks)

          -  Who is not pregnant

          -  Who can report seizure diary by him/herself or caregiver

          -  Who agree to this trial and provide informed consent.

          -  Type of seizures : of generalized tonic-clonic, complex partial, and/or simple partial
             motor seizures;

        Exclusion Criteria:

          -  Who has progressive CNS disease.

          -  Has serious systemic or psychiatric disease

          -  Who is not suitable by investigator(uncooperative)

          -  Who can not fill up diary check card

          -  Is pregnant, breastfeeding, or planning to become pregnant

          -  Exclusion - absence s. juvenile myoclonic epilepsy, atonic seizure, alcohol or other
             substance abusers, mental retardation etc.

          -  Who cancels to agree to this trial and provide informed consent.

          -  ALT, AST, bilirubin and BUN/Cr levels are more than twice normal range of them

          -  WBC value is 2000 and less, Hb value is 9.0 and less, platelet count is 100,000 and
             less in CBC

          -  Who took investigation products before participating this study
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>16 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Byung-In Lee</last_name>
    <role>Principal Investigator</role>
    <affiliation>Yonsei Univ.</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Kyoung Heo</last_name>
    <role>Principal Investigator</role>
    <affiliation>Yonsei Univ.</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Sang-Kun Lee</last_name>
    <role>Principal Investigator</role>
    <affiliation>Seoul National Univ.</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Sang-Ahm Lee</last_name>
    <role>Principal Investigator</role>
    <affiliation>Ulsan Univ.</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Dong-Jin Shin</last_name>
    <role>Principal Investigator</role>
    <affiliation>Gacheon Univ.</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Hong-Ki Song</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hallym Univ.</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Young-In Kim</last_name>
    <role>Principal Investigator</role>
    <affiliation>Catholic Univ.</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Se-Jin Lee</last_name>
    <role>Principal Investigator</role>
    <affiliation>Youngnam Univ.</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Sang-Ho Kim</last_name>
    <role>Principal Investigator</role>
    <affiliation>Donga Univ.</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Myung-Gyu Kim</last_name>
    <role>Principal Investigator</role>
    <affiliation>Cheonnam Univ.</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Yo-Sik Kim</last_name>
    <role>Principal Investigator</role>
    <affiliation>Wonkwang Univ.</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Sang-Do Lee</last_name>
    <role>Principal Investigator</role>
    <affiliation>Dongsan Hosp.</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Sung-Eun Kim</last_name>
    <role>Principal Investigator</role>
    <affiliation>Pusan-Bak Hosp.</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Sung-Pa Park</last_name>
    <role>Principal Investigator</role>
    <affiliation>Kyungbuk Univ.</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Joo-Yong Kim</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hanrim Univ.</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Ok-Jun Kim</last_name>
    <role>Principal Investigator</role>
    <affiliation>Bundang Cha</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Soon-Ki Noh</last_name>
    <role>Principal Investigator</role>
    <affiliation>Bong-Sang Hosp.</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Hyang-Woon Lee</last_name>
    <role>Principal Investigator</role>
    <affiliation>I-wha Univ.</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Jae-Moon Kim</last_name>
    <role>Principal Investigator</role>
    <affiliation>Chungnam Univ.</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Yonsei Medical Center</name>
      <address>
        <city>Seoul</city>
        <zip>120-752</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>June 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 28, 2008</study_first_submitted>
  <study_first_submitted_qc>December 12, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 15, 2008</study_first_posted>
  <results_first_submitted>January 20, 2014</results_first_submitted>
  <results_first_submitted_qc>May 11, 2015</results_first_submitted_qc>
  <results_first_posted type="Estimate">May 29, 2015</results_first_posted>
  <last_update_submitted>June 29, 2015</last_update_submitted>
  <last_update_submitted_qc>June 29, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">July 27, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Epilepsy</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lamotrigine</mesh_term>
    <mesh_term>Anticonvulsants</mesh_term>
    <mesh_term>Valproic Acid</mesh_term>
    <mesh_term>Carbamazepine</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Carbamazepine</title>
          <description>Carbamazepine 100mg/day for the first two weeks. At next two weeks, dose of Carbamazepine was increased to 200mg/day in two divided doses</description>
        </group>
        <group group_id="P2">
          <title>Lamotrigine/Valproate</title>
          <description>Lamotrigine and Valproate combination therapy
Lamotrigine 25mg/day for the first two weeks. At next two weeks, LTG 50 mg once a day</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="107"/>
                <participants group_id="P2" count="100"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="104"/>
                <participants group_id="P2" count="98"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="2"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Carbamazepine</title>
          <description>Carbamazepine
Carbamazepine</description>
        </group>
        <group group_id="B2">
          <title>Lamotrigine/Valproate</title>
          <description>Lamotrigine and Valproate combination therapy
Lamotrigine/Valproate</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="104"/>
            <count group_id="B2" value="98"/>
            <count group_id="B3" value="202"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Year</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="33.2" spread="14.6"/>
                    <measurement group_id="B2" value="36.5" spread="13.7"/>
                    <measurement group_id="B3" value="34.8" spread="14.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="51"/>
                    <measurement group_id="B2" value="48"/>
                    <measurement group_id="B3" value="99"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="53"/>
                    <measurement group_id="B2" value="50"/>
                    <measurement group_id="B3" value="103"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Korea, Republic of</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="104"/>
                    <measurement group_id="B2" value="98"/>
                    <measurement group_id="B3" value="202"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Retention Rate After 52 Weeks Maintenance Period</title>
        <description>* Retention rate means completion rate (CR), the proportion of patients who have completed the 60-week study as planned.</description>
        <time_frame>52 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Carbamazepine</title>
            <description>Carbamazepine
Carbamazepine</description>
          </group>
          <group group_id="O2">
            <title>Lamotrigine/Valproate</title>
            <description>Lamotrigine and Valproate combination therapy
Lamotrigine/Valproate</description>
          </group>
        </group_list>
        <measure>
          <title>Retention Rate After 52 Weeks Maintenance Period</title>
          <description>* Retention rate means completion rate (CR), the proportion of patients who have completed the 60-week study as planned.</description>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="104"/>
                <count group_id="O2" value="98"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="104"/>
                    <measurement group_id="O2" value="98"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Seizure Free Rate for 24 Weeks at Initial Target Dose</title>
        <time_frame>24 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Carbamazepine</title>
            <description>Carbamazepine
Carbamazepine</description>
          </group>
          <group group_id="O2">
            <title>Lamotrigine/Valproate</title>
            <description>Lamotrigine and Valproate combination therapy
Lamotrigine/Valproate</description>
          </group>
        </group_list>
        <measure>
          <title>Seizure Free Rate for 24 Weeks at Initial Target Dose</title>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="90"/>
                <count group_id="O2" value="78"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="51"/>
                    <measurement group_id="O2" value="59"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Seizure Free Rate for 52 Weeks at Initial Target Dose</title>
        <time_frame>52 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Carbamazepine</title>
            <description>Carbamazepine
Carbamazepine</description>
          </group>
          <group group_id="O2">
            <title>Lamotrigine/Valproate</title>
            <description>Lamotrigine and Valproate combination therapy
Lamotrigine/Valproate</description>
          </group>
        </group_list>
        <measure>
          <title>Seizure Free Rate for 52 Weeks at Initial Target Dose</title>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="90"/>
                <count group_id="O2" value="78"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="43"/>
                    <measurement group_id="O2" value="50"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>52 weeks</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Carbamazepine</title>
          <description>Carbamazepine
Carbamazepine</description>
        </group>
        <group group_id="E2">
          <title>Lamotrigine/Valproate</title>
          <description>Lamotrigine and Valproate combination therapy
Lamotrigine/Valproate</description>
        </group>
      </group_list>
      <serious_events>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="104"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="98"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Ventricular tachycardia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="104"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="98"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Meningoencephalitis herpetic</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="104"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="98"/>
              </event>
              <event>
                <sub_title>Pneumonia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="104"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="98"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Joint dislocation</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="104"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="98"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Facet joint syndrome</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="104"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="98"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Alcoholic seizure</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="104"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="98"/>
              </event>
              <event>
                <sub_title>Atonic seizures</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="104"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="98"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Abnormal behaviour</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="104"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="98"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Skin rash</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="104"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="98"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Surgical and medical procedures</title>
            <event_list>
              <event>
                <sub_title>Hospitalisation</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="104"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="98"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="60" subjects_at_risk="104"/>
                <counts group_id="E2" subjects_affected="59" subjects_at_risk="98"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Dyspepsia</sub_title>
                <counts group_id="E1" events="8" subjects_affected="7" subjects_at_risk="104"/>
                <counts group_id="E2" events="7" subjects_affected="5" subjects_at_risk="98"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" events="10" subjects_affected="10" subjects_at_risk="104"/>
                <counts group_id="E2" events="5" subjects_affected="4" subjects_at_risk="98"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Nasopharyngitis</sub_title>
                <counts group_id="E1" events="9" subjects_affected="7" subjects_at_risk="104"/>
                <counts group_id="E2" events="26" subjects_affected="10" subjects_at_risk="98"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Weight gain</sub_title>
                <counts group_id="E1" events="9" subjects_affected="9" subjects_at_risk="104"/>
                <counts group_id="E2" events="6" subjects_affected="6" subjects_at_risk="98"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" events="29" subjects_affected="26" subjects_at_risk="104"/>
                <counts group_id="E2" events="52" subjects_affected="26" subjects_at_risk="98"/>
              </event>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" events="23" subjects_affected="18" subjects_at_risk="104"/>
                <counts group_id="E2" events="18" subjects_affected="17" subjects_at_risk="98"/>
              </event>
              <event>
                <sub_title>Somnolence</sub_title>
                <counts group_id="E1" events="15" subjects_affected="14" subjects_at_risk="104"/>
                <counts group_id="E2" events="12" subjects_affected="12" subjects_at_risk="98"/>
              </event>
              <event>
                <sub_title>Memory impairment</sub_title>
                <counts group_id="E1" events="14" subjects_affected="10" subjects_at_risk="104"/>
                <counts group_id="E2" events="5" subjects_affected="5" subjects_at_risk="98"/>
              </event>
              <event>
                <sub_title>Tremor</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="104"/>
                <counts group_id="E2" events="11" subjects_affected="11" subjects_at_risk="98"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Skin rash</sub_title>
                <counts group_id="E1" events="7" subjects_affected="7" subjects_at_risk="104"/>
                <counts group_id="E2" events="6" subjects_affected="6" subjects_at_risk="98"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>The only disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is more than 60 days but less than or equal to 180 days. The sponsor cannot require changes to the communication and cannot extend the embargo.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Dr. Yoon</name_or_title>
      <organization>Yonsei University Severance Hospital</organization>
      <email>BILEE@yuhs.ac</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

